IndustryCompany release

XORTX Therapeutics warns of going-concern doubt as cash falls to $318,846

XORTX Therapeutics Inc. (XRTX) · Mon 16 Nov 2026

The gout and kidney disease developer reports a nine-month net loss of about $2.88M, after a share consolidation and a voluntary TSX Venture delisting.

XORTX Therapeutics, a late-stage company developing therapies for gout and kidney disease, has filed unaudited interim financial statements for the nine months ended 30 September 2026. The statements show a net loss of about $2.88M and cash of $318,846.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): XORTX Therapeutics Inc. ↗

Article written by VigiEye from the official source (XORTX Therapeutics Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →